Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADCGlobe Newswire • 18 days ago
Study enrolling patients with metastatic urothelial cancer (mUC) and other Nectin-4 enriched tumorsEmerging clinical profile from CSPC's Phase 1 China study indicates differentiation from PADCEV...
Share to Feed
This indicator may be signaling that CRBP's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...
This is a Bearish indicator signaling CRBP's price could decline from here. Traders may explore shorting the stock or put options...
This is a signal that CRBP's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...
This is a signal that CRBP's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...
Encouraging CRB-701 (SYS6002) First-in-Human Data Presented at ASCO-GU 2024; first patient expected to be dosed in US Ph1 study by end of March 2024 IND Application for CRB-601 cleared; Ph1...
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP Get Free Report) major shareholder Cormorant Asset Management, Lp bought 250,000 shares of the stock in a transaction that occurred on...
This is a signal that CRBP's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...
This is a signal that CRBP's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...
This price move could be a signal that CRBP may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...